FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387610825> ?p ?o ?g. }

• W4387610825 endingPage "14" @default.
• W4387610825 startingPage "1" @default.
• W4387610825 abstract "OBJECTIVE Only one phase III prospective randomized study, published in 2006, has assessed the performance of 5-aminolevulinic acid (5-ALA) fluorescence–guided surgery (FGS) for glioblastoma resection. The aim of the RESECT study was to compare the onco-functional results associated with 5-ALA fluorescence and with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care. METHODS This was a phase III prospective randomized single-blinded study, involving 21 French neurosurgical centers, comparing 5-ALA FGS with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care, including neuronavigation use and postoperative radiochemotherapy. Randomization was performed in a 1:1 ratio stratified by institution. 5-ALA (20 mg/kg) or placebo (ascorbic acid) was administered orally 3–5 hours before the incision. The primary endpoint was the rate of gross-total resection (GTR) blindly assessed by an independent committee. Patients without a confirmed pathological diagnosis of glioblastoma or with unavailable postoperative MRI studies were excluded from the per-protocol analysis. RESULTS Between March 2013 and August 2016, a total of 171 patients were assigned to the 5-ALA fluorescence group (n = 88) or to the placebo group (n = 83). Twenty-four cases were excluded because the WHO histological criteria of grade 4 glioma were not met. The proportion of GTR was significantly higher in the 5-ALA fluorescence group (53/67, 79.1%) than in the placebo group (33/69, 47.8%; p = 0.0002). After adjustment for age, preoperative Karnofsky Performance Scale score, and tumor location, GTR was still associated with 5-ALA fluorescence (OR 4.13 [95% CI 1.94–8.79]). The mean 7-day postoperative Karnofsky Performance Scale score (≥ 80% in 49/71, 69.0% [5-ALA group]; 50/71, 70.4% [placebo group], p = 0.86) and the proportion of patients with a worsened neurological status 3 months postoperatively (9/68, 13.2% [5-ALA group]; 9/70, 12.9% [placebo group], p = 0.95) were similar between groups. Adverse events related to 5-ALA intake were rare and consisted of photosensitization in 4/87 (4.6%) patients and hepatic cytolysis in 1/87 (1.1%) patients. The 6-month PFS (70.2% [95% CI 57.7%–79.6%] and 68.4% [95% CI 55.7%–78.1%]; p = 0.39) and 24-month OS (30.1% [95% CI 18.9%–42.0%] and 37.7% [95% CI 25.8%–49.5%]; p = 0.89) did not significantly differ. In multivariate analysis, GTR was an independent predictor of PFS (hazard ratio 0.56 [95% CI 0.36–0.86], p = 0.008) and OS (hazard ratio 0.65 [95% CI 0.42–1.01], p = 0.05). The use of 5-ALA FGS generates a significant extra cost of 2732.36€ (95% CI 1658.40€–3794.11€). CONCLUSIONS The authors found that 5-ALA FGS is an easy-to-use, cost-effective, and minimally time-consuming technique that safely optimizes the extent of resection in patients harboring glioblastoma amenable to a large resection." @default.
• W4387610825 created "2023-10-14" @default.
• W4387610825 creator A5003020683 @default.
• W4387610825 creator A5004526028 @default.
• W4387610825 creator A5006456322 @default.
• W4387610825 creator A5007522013 @default.
• W4387610825 creator A5008857104 @default.
• W4387610825 creator A5011110394 @default.
• W4387610825 creator A5014368290 @default.
• W4387610825 creator A5017501315 @default.
• W4387610825 creator A5020440025 @default.
• W4387610825 creator A5026149293 @default.
• W4387610825 creator A5028622664 @default.
• W4387610825 creator A5029543254 @default.
• W4387610825 creator A5030867801 @default.
• W4387610825 creator A5032160688 @default.
• W4387610825 creator A5033136856 @default.
• W4387610825 creator A5033291676 @default.
• W4387610825 creator A5033450071 @default.
• W4387610825 creator A5035922112 @default.
• W4387610825 creator A5036261277 @default.
• W4387610825 creator A5040578116 @default.
• W4387610825 creator A5041053243 @default.
• W4387610825 creator A5047191938 @default.
• W4387610825 creator A5049734850 @default.
• W4387610825 creator A5051605080 @default.
• W4387610825 creator A5052045873 @default.
• W4387610825 creator A5054871359 @default.
• W4387610825 creator A5055824130 @default.
• W4387610825 creator A5062246969 @default.
• W4387610825 creator A5071467065 @default.
• W4387610825 creator A5073443364 @default.
• W4387610825 creator A5074906030 @default.
• W4387610825 creator A5077011745 @default.
• W4387610825 creator A5082315568 @default.
• W4387610825 creator A5086642518 @default.
• W4387610825 creator A5087397869 @default.
• W4387610825 creator A5087873024 @default.
• W4387610825 date "2023-10-01" @default.
• W4387610825 modified "2023-10-14" @default.
• W4387610825 title "Use of 5-ALA fluorescence–guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study" @default.
• W4387610825 cites W2326952007 @default.
• W4387610825 doi "https://doi.org/10.3171/2023.7.jns231170" @default.
• W4387610825 hasPublicationYear "2023" @default.
• W4387610825 type Work @default.
• W4387610825 citedByCount "0" @default.
• W4387610825 crossrefType "journal-article" @default.
• W4387610825 hasAuthorship W4387610825A5003020683 @default.
• W4387610825 hasAuthorship W4387610825A5004526028 @default.
• W4387610825 hasAuthorship W4387610825A5006456322 @default.
• W4387610825 hasAuthorship W4387610825A5007522013 @default.
• W4387610825 hasAuthorship W4387610825A5008857104 @default.
• W4387610825 hasAuthorship W4387610825A5011110394 @default.
• W4387610825 hasAuthorship W4387610825A5014368290 @default.
• W4387610825 hasAuthorship W4387610825A5017501315 @default.
• W4387610825 hasAuthorship W4387610825A5020440025 @default.
• W4387610825 hasAuthorship W4387610825A5026149293 @default.
• W4387610825 hasAuthorship W4387610825A5028622664 @default.
• W4387610825 hasAuthorship W4387610825A5029543254 @default.
• W4387610825 hasAuthorship W4387610825A5030867801 @default.
• W4387610825 hasAuthorship W4387610825A5032160688 @default.
• W4387610825 hasAuthorship W4387610825A5033136856 @default.
• W4387610825 hasAuthorship W4387610825A5033291676 @default.
• W4387610825 hasAuthorship W4387610825A5033450071 @default.
• W4387610825 hasAuthorship W4387610825A5035922112 @default.
• W4387610825 hasAuthorship W4387610825A5036261277 @default.
• W4387610825 hasAuthorship W4387610825A5040578116 @default.
• W4387610825 hasAuthorship W4387610825A5041053243 @default.
• W4387610825 hasAuthorship W4387610825A5047191938 @default.
• W4387610825 hasAuthorship W4387610825A5049734850 @default.
• W4387610825 hasAuthorship W4387610825A5051605080 @default.
• W4387610825 hasAuthorship W4387610825A5052045873 @default.
• W4387610825 hasAuthorship W4387610825A5054871359 @default.
• W4387610825 hasAuthorship W4387610825A5055824130 @default.
• W4387610825 hasAuthorship W4387610825A5062246969 @default.
• W4387610825 hasAuthorship W4387610825A5071467065 @default.
• W4387610825 hasAuthorship W4387610825A5073443364 @default.
• W4387610825 hasAuthorship W4387610825A5074906030 @default.
• W4387610825 hasAuthorship W4387610825A5077011745 @default.
• W4387610825 hasAuthorship W4387610825A5082315568 @default.
• W4387610825 hasAuthorship W4387610825A5086642518 @default.
• W4387610825 hasAuthorship W4387610825A5087397869 @default.
• W4387610825 hasAuthorship W4387610825A5087873024 @default.
• W4387610825 hasConcept C141071460 @default.
• W4387610825 hasConcept C142724271 @default.
• W4387610825 hasConcept C168563851 @default.
• W4387610825 hasConcept C188816634 @default.
• W4387610825 hasConcept C203092338 @default.
• W4387610825 hasConcept C204243189 @default.
• W4387610825 hasConcept C204787440 @default.
• W4387610825 hasConcept C27081682 @default.
• W4387610825 hasConcept C2776194525 @default.
• W4387610825 hasConcept C2778227246 @default.
• W4387610825 hasConcept C2781437307 @default.
• W4387610825 hasConcept C502942594 @default.
• W4387610825 hasConcept C71924100 @default.
• W4387610825 hasConceptScore W4387610825C141071460 @default.
• W4387610825 hasConceptScore W4387610825C142724271 @default.

• next